Literature DB >> 34021002

Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing Sarcoma.

Olivier Delattre1, Dimiter S Dimitrov2, Hai-Feng Zhang3,4, Christopher S Hughes3,4, Wei Li2, Jian-Zhong He5, Didier Surdez1,6, Amal M El-Naggar3,4, Hongwei Cheng4,7, Anna Prudova4,8, Alberto Delaidelli3,4, Gian Luca Negri8, Xiaojun Li4, Maj Sofie Ørum-Madsen9, Michael M Lizardo4, Htoo Zarni Oo9, Shane Colborne8, Taras Shyp3,4, Renata Scopim-Ribeiro3,4, Colin A Hammond10, Anne-Chloe Dhez3,4, Sofya Langman3,4, Jonathan K M Lim3,4, Sonia H Y Kung9, Amy Li3,4, Anne Steino4, Mads Daugaard9,4, Seth J Parker3,11, Ramon I Klein Geltink3,11, Rimas J Orentas12,4, Li-Yan Xu5, Gregg B Morin8,13, Poul H Sorensen14,4.   

Abstract

Cancer cells must overcome anoikis (detachment-induced death) to successfully metastasize. Using proteomic screens, we found that distinct oncoproteins upregulate IL1 receptor accessory protein (IL1RAP) to suppress anoikis. IL1RAP is directly induced by oncogenic fusions of Ewing sarcoma, a highly metastatic childhood sarcoma. IL1RAP inactivation triggers anoikis and impedes metastatic dissemination of Ewing sarcoma cells. Mechanistically, IL1RAP binds the cell-surface system Xc - transporter to enhance exogenous cystine uptake, thereby replenishing cysteine and the glutathione antioxidant. Under cystine depletion, IL1RAP induces cystathionine gamma lyase (CTH) to activate the transsulfuration pathway for de novo cysteine synthesis. Therefore, IL1RAP maintains cyst(e)ine and glutathione pools, which are vital for redox homeostasis and anoikis resistance. IL1RAP is minimally expressed in pediatric and adult normal tissues, and human anti-IL1RAP antibodies induce potent antibody-dependent cellular cytotoxicity of Ewing sarcoma cells. Therefore, we define IL1RAP as a new cell-surface target in Ewing sarcoma, which is potentially exploitable for immunotherapy. SIGNIFICANCE: Here, we identify cell-surface protein IL1RAP as a key driver of metastasis in Ewing sarcoma, a highly aggressive childhood sarcoma. Minimal expression in pediatric and adult normal tissues nominates IL1RAP as a promising target for immunotherapy.See related commentary by Yoon and DeNicola, p. 2679.This article is highlighted in the In This Issue feature, p. 2659. ©2021 The Authors; Published by the American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34021002      PMCID: PMC8563374          DOI: 10.1158/2159-8290.CD-20-1690

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  60 in total

1.  Cancer-Specific Retargeting of BAF Complexes by a Prion-like Domain.

Authors:  Gaylor Boulay; Gabriel J Sandoval; Nicolo Riggi; Sowmya Iyer; Rémi Buisson; Beverly Naigles; Mary E Awad; Shruthi Rengarajan; Angela Volorio; Matthew J McBride; Liliane C Broye; Lee Zou; Ivan Stamenkovic; Cigall Kadoch; Miguel N Rivera
Journal:  Cell       Date:  2017-08-24       Impact factor: 41.582

2.  Oncogenic PI3K promotes methionine dependency in breast cancer cells through the cystine-glutamate antiporter xCT.

Authors:  Evan C Lien; Laura Ghisolfi; Renee C Geck; John M Asara; Alex Toker
Journal:  Sci Signal       Date:  2017-12-19       Impact factor: 8.192

3.  Ferroptosis as a p53-mediated activity during tumour suppression.

Authors:  Le Jiang; Ning Kon; Tongyuan Li; Shang-Jui Wang; Tao Su; Hanina Hibshoosh; Richard Baer; Wei Gu
Journal:  Nature       Date:  2015-03-18       Impact factor: 49.962

4.  CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth.

Authors:  Takatsugu Ishimoto; Osamu Nagano; Toshifumi Yae; Mayumi Tamada; Takeshi Motohara; Hiroko Oshima; Masanobu Oshima; Tatsuya Ikeda; Rika Asaba; Hideki Yagi; Takashi Masuko; Takatsune Shimizu; Tomoki Ishikawa; Kazuharu Kai; Eri Takahashi; Yu Imamura; Yoshifumi Baba; Mitsuyo Ohmura; Makoto Suematsu; Hideo Baba; Hideyuki Saya
Journal:  Cancer Cell       Date:  2011-03-08       Impact factor: 31.743

5.  Cysteine depletion induces pancreatic tumor ferroptosis in mice.

Authors:  Michael A Badgley; Daniel M Kremer; H Carlo Maurer; Kathleen E DelGiorno; Ho-Joon Lee; Vinee Purohit; Irina R Sagalovskiy; Alice Ma; Jonathan Kapilian; Christina E M Firl; Amanda R Decker; Steve A Sastra; Carmine F Palermo; Leonardo R Andrade; Peter Sajjakulnukit; Li Zhang; Zachary P Tolstyka; Tal Hirschhorn; Candice Lamb; Tong Liu; Wei Gu; E Scott Seeley; Everett Stone; George Georgiou; Uri Manor; Alina Iuga; Geoffrey M Wahl; Brent R Stockwell; Costas A Lyssiotis; Kenneth P Olive
Journal:  Science       Date:  2020-04-03       Impact factor: 47.728

Review 6.  Emerging Biological Principles of Metastasis.

Authors:  Arthur W Lambert; Diwakar R Pattabiraman; Robert A Weinberg
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

7.  The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility.

Authors:  Chun-Shik Shin; Prashant Mishra; Jeramie D Watrous; Valerio Carelli; Marilena D'Aurelio; Mohit Jain; David C Chan
Journal:  Nat Commun       Date:  2017-04-21       Impact factor: 14.919

8.  Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability.

Authors:  Mark R Sullivan; Laura V Danai; Caroline A Lewis; Sze Ham Chan; Dan Y Gui; Tenzin Kunchok; Emily A Dennstedt; Matthew G Vander Heiden; Alexander Muir
Journal:  Elife       Date:  2019-04-16       Impact factor: 8.140

9.  Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance.

Authors:  Jonathan K M Lim; Alberto Delaidelli; Sean W Minaker; Hai-Feng Zhang; Milena Colovic; Hua Yang; Gian Luca Negri; Silvia von Karstedt; William W Lockwood; Paul Schaffer; Gabriel Leprivier; Poul H Sorensen
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-18       Impact factor: 11.205

10.  Sulfur sequestration promotes multicellularity during nutrient limitation.

Authors:  Beth Kelly; Gustavo E Carrizo; Joy Edwards-Hicks; David E Sanin; Michal A Stanczak; Chantal Priesnitz; Lea J Flachsmann; Jonathan D Curtis; Gerhard Mittler; Yaarub Musa; Thomas Becker; Joerg M Buescher; Erika L Pearce
Journal:  Nature       Date:  2021-02-24       Impact factor: 49.962

View more
  8 in total

1.  Arginine methylation of MTHFD1 by PRMT5 enhances anoikis resistance and cancer metastasis.

Authors:  Qi Meng; Yun-Xin Lu; Chen Wei; Zi-Xian Wang; Jin-Fei Lin; Kun Liao; Xiao-Jing Luo; Kai Yu; Yi Han; Jia-Jun Li; Yue-Tao Tan; Hao Li; Zhao-Lei Zeng; Bo Li; Rui-Hua Xu; Huai-Qiang Ju
Journal:  Oncogene       Date:  2022-07-07       Impact factor: 8.756

Review 2.  Emerging roles of cystathionine β-synthase in various forms of cancer.

Authors:  Kelly Ascenção; Csaba Szabo
Journal:  Redox Biol       Date:  2022-05-10       Impact factor: 10.787

Review 3.  Latest developments in the pathobiology of Ewing sarcoma.

Authors:  Irina Karlina; Brett A Schroeder; Kirill Kirgizov; Olga Romantsova; Andrey L Istranov; Andrey Nedorubov; Peter Timashev; Ilya Ulasov
Journal:  J Bone Oncol       Date:  2022-07-01       Impact factor: 4.491

4.  TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR.

Authors:  Tao Zhang; Bofang Wang; Fei Su; Baohong Gu; Lin Xiang; Lei Gao; Peng Zheng; Xue-Mei Li; Hao Chen
Journal:  Int J Biol Sci       Date:  2022-07-11       Impact factor: 10.750

Review 5.  Epigenetic and Transcriptional Signaling in Ewing Sarcoma-Disease Etiology and Therapeutic Opportunities.

Authors:  Mingli Li; Chun-Wei Chen
Journal:  Biomedicines       Date:  2022-06-05

Review 6.  Transsulfuration, minor player or crucial for cysteine homeostasis in cancer.

Authors:  Hai-Feng Zhang; Ramon I Klein Geltink; Seth J Parker; Poul H Sorensen
Journal:  Trends Cell Biol       Date:  2022-03-29       Impact factor: 21.167

Review 7.  Mechanisms, Diagnosis and Treatment of Bone Metastases.

Authors:  Jozef Ban; Valerie Fock; Dave N T Aryee; Heinrich Kovar
Journal:  Cells       Date:  2021-10-29       Impact factor: 6.600

8.  Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia.

Authors:  Rim Trad; Walid Warda; Vincent Alcazer; Mathieu Neto da Rocha; Ana Berceanu; Clémentine Nicod; Rafik Haderbache; Xavier Roussel; Yohan Desbrosses; Etienne Daguindau; Florain Renosi; Christophe Roumier; Lucie Bouquet; Sabeha Biichle; Melanie Guiot; Evan Seffar; Denis Caillot; Stephane Depil; Eric Robinet; Yahya Salma; Eric Deconinck; Marina Deschamps; Christophe Ferrand
Journal:  J Immunother Cancer       Date:  2022-07       Impact factor: 12.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.